

PRIOR AUTHORIZATION REQUEST FORM CARISOPRODOL FOR HEALTHY U

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694				
, , , , , , , , , , , , , , , , , , , ,				
Date:	Member Name:		ID#:	
DOB:	Gender:		Physician:	
Office Phone:	Office Fax:		Office Contact:	
Height/Weight:				
Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: carisoprodol, carisoprodol/aspirin, carisoprodol/aspirin/codeine Dosing/Frequency:				
If the request is for reauthorization, proceed to reauthorization section.				
Questions		Yes	No	Comments/Notes
1. Does the member have a history of 365 days?	substance abuse in the last			
2. Is the member 16 years of age or old	der?			
3. Has the member had carisoprodol-c by more than 2 prescribers in the la				
4. Has the member had a trial and failu contraindication/intolerance to, at I relaxants (baclofen, cyclobenzaprine etc.)?	ure of, east 3 preferred muscle			Please provide documentation
5. Will the member be taking carisopro opioid or benzodiazepine?	odol in combination with an			
What medications and/or treatment name of treatment, reason for failure,		the past	for this	s condition? Please document

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.



Additional information:
Dhysisian Cignatura
Physician Signature:

Policy PHARM- 096

Origination Date: 06/18/2020 Reviewed/Revised Date: 08/18/2021 Next Review Date: 08/18/2022 Current Effective Date: 09/01/2021

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

^{**}Failure to submit clinical documentation to support this request will result in delay and/or denial of the request**